Last reviewed · How we verify
Placebo-Oral
Placebo-Oral is a Small molecule drug developed by Eli Lilly and Company. It is currently FDA-approved for Clinical trial control comparator (not a therapeutic indication). Also known as: Placebo, XP19986 matching placebo, Uralyt-U, Placebo (aluminum hydroxide).
Placebo produces no pharmacological effect and works entirely through the placebo effect, a psychobiological response to the expectation of treatment.
Placebo produces no pharmacological effect and works entirely through the placebo effect, a psychobiological response to the expectation of treatment. Used for Clinical trial control comparator (not a therapeutic indication).
At a glance
| Generic name | Placebo-Oral |
|---|---|
| Also known as | Placebo, XP19986 matching placebo, Uralyt-U, Placebo (aluminum hydroxide) |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance that contains no active pharmaceutical ingredient. Its therapeutic effects, when observed, arise from the patient's psychological expectation of benefit, activation of endogenous healing mechanisms, and contextual factors in the clinical setting rather than from direct molecular action. Placebo is used as a control comparator in clinical trials to distinguish true drug efficacy from placebo response.
Approved indications
- Clinical trial control comparator (not a therapeutic indication)
Common side effects
- Nocebo effects (adverse events attributed to placebo expectation)
Key clinical trials
- Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease (NA)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype (NA)
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-Oral CI brief — competitive landscape report
- Placebo-Oral updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Placebo-Oral
What is Placebo-Oral?
How does Placebo-Oral work?
What is Placebo-Oral used for?
Who makes Placebo-Oral?
Is Placebo-Oral also known as anything else?
What development phase is Placebo-Oral in?
What are the side effects of Placebo-Oral?
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Indication: Drugs for Clinical trial control comparator (not a therapeutic indication)
- Also known as: Placebo, XP19986 matching placebo, Uralyt-U, Placebo (aluminum hydroxide)
- Compare: Placebo-Oral vs similar drugs
- Pricing: Placebo-Oral cost, discount & access